Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2014-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2014年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 年半年度报告全文" which translates to "2014 Semi-Annual Report Full Text." It contains detailed financial data, management discussion, business analysis, investment status, and other comprehensive information typical of an interim or quarterly report. The document includes actual financial statements, performance metrics, and management commentary for the half-year period ending June 30, 2014. It is not a brief announcement or a certification letter but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-25 Chinese
2014年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '华兰生物工程股份有限公司 2014 年1-6 月财务报表 （未经审计）', which translates to 'Hualan Biological Engineering Co., Ltd. 2014 January to June Financial Statements (Unaudited)'. It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and shareholders' equity changes for the half-year period ending June 30, 2014. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year (six months) indicates this is an Interim / Quarterly Report. The document is lengthy (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-25 Chinese
减资公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the company's reduction of registered capital due to the repurchase and cancellation of restricted shares held by a former employee. It includes details about the board meeting approval, the change in total shares, and a notification to creditors about their rights. The document is short (736 characters) and serves as an official notice of a capital change event rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2014-08-05 Chinese
2014年半年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2014 年半年度业绩快报' which translates to '2014 Half-Year Performance Express Report'. It contains preliminary financial data for the half-year period of 2014, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and unaudited, and it references a prior quarterly report. The length is 1329 characters, which is quite short and typical for a performance express report rather than a full interim report. The document includes financial highlights and a brief explanation of performance but does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR). It also mentions internal audit reports and signed financial statements as backup documents but does not include them in the text. Given the short length and nature of the content, this document fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, rather than a full interim report or annual report. Therefore, the classification is Earnings Release (ER) with high confidence. H1 2014
2014-07-30 Chinese
独立董事关于第五届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding specific matters discussed at the company's fifth board of directors' eleventh meeting. It focuses on the legality and compliance of stock repurchase and restricted stock grants under the company's stock incentive plan. The document does not contain financial statements or comprehensive financial data, nor is it a report of financial results or an announcement of voting results. It is a formal opinion related to board/management decisions about stock incentives, which aligns with Board/Management Information filings. The document length is short (1021 characters), and it is not an announcement of a report publication or a certification letter. Therefore, the most appropriate classification is Board/Management Information (MANG).
2014-07-17 Chinese
关于向激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the granting of reserved restricted shares under a stock incentive plan by the company's board of directors. It details the number of shares, grant price, eligibility, approval procedures, and legal opinions related to the stock incentive plan. There are no financial statements or comprehensive financial performance data included. The document is a formal announcement of a capital/financing activity (stock incentive grant) rather than a full report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief notice or a regulatory filing but a substantive announcement about financing-related stock grants.
2014-07-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.